Visus Therapeutics, an American pharmaceutical company based in Seattle, announced yesterday the completion of a $36 million financing round to fund the company’s research on its Brimochol product, an eye drop drug designed to correct the effects of presbyopia with one daily application. The drug is currently in the second phase of its development, with an application for approval by the Food & Drug & Administration (FDA) scheduled upon completion of Phase 3. Johnson & Johnson Innovation - JJDC, a division of the eponymous group, took part in the round, along with investment funds and the company’s existing shareholders. The announcement by Visus Therapeutics comes just a few days after Allergan filed an FDA application for a presbyopia-treating solution.